Efficacy and safety of tyrosine kinase inhibitors (dasatinib, nilotinib) in the treatment of chronic phase chronic myeloid leukemia

Abstract

Current treatment options for chronic myeloid leukemia (CML) with imatinib allowed achieving long-term progression-free and overall survival and improved patient quality of life. In cases of imatinib resistance therapy with second-generation tyrosine kinases inhibitors – dasatinib and nilotinib – is also possible. The article represents a literature review evaluating efficacy and toxicity of both drugs and highlighting some of the practical issues of CML treatment after first-line therapy failure.

Keywords

• chronic myeloid leukemia
• dasatinib
• nilotinib